Cargando…

Breakthrough COVID-19 case after full-dose administration of CoronaVac vaccine

Detalles Bibliográficos
Autores principales:	Ulhaq, Zulvikar Syambani, Soraya, Gita Vita, Indriana, Kristin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Indian Association of Medical Microbiologists. Published by Elsevier B.V. 2021
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176381/ https://www.ncbi.nlm.nih.gov/pubmed/34099338 http://dx.doi.org/10.1016/j.ijmmb.2021.05.017

Ejemplares similares

Interleukin-6 as a potential biomarker of COVID-19 progression
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2020)

The prevalence of ophthalmic manifestations in COVID-19 and the diagnostic value of ocular tissue/fluid
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2020)

Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2020)

Crucial laboratory parameters in COVID-19 diagnosis and prognosis: An updated meta-analysis
por: Soraya, Gita Vita, et al.
Publicado: (2020)

Crucial laboratory parameters in COVID-19 diagnosis and prognosis: An updated meta-analysis
por: Soraya, Gita Vita, et al.
Publicado: (2020)

Interleukin-6 levels in children developing SARS-CoV-2 infection
por: Soraya, Gita Vita, et al.
Publicado: (2020)

Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2020)

An urgent call to identify the probable cause of severe acute hepatitis outbreak in children
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2022)

Minimal change disease following vaccination with CoronaVac
por: Dirim, Ahmet Burak, et al.
Publicado: (2021)

Immunogenicity, reactogenicity and breakthrough infections after two doses of the inactivated CoronaVac vaccine among patients on dialysis: phase 4 study
por: Medina-Pestana, José, et al.
Publicado: (2021)

Cutaneous reactions after CoronaVac and BioNTech vaccines
por: Öner, Ümran, et al.
Publicado: (2022)

Leukocytoclastic vasculitis after the third dose of CoronaVac vaccination
por: Oskay, T., et al.
Publicado: (2021)

Nanotheranostics: A powerful next-generation solution to tackle hepatocellular carcinoma
por: Ladju, Rusdina Bte, et al.
Publicado: (2022)

A Randomized Clinical Trial Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac
por: Mok, Chris Ka Pun, et al.
Publicado: (2022)

The role of IL-6-174 G/C polymorphism and intraocular IL-6 levels in the pathogenesis of ocular diseases: a systematic review and meta-analysis
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2020)

Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial
por: Samoud, Samar, et al.
Publicado: (2023)

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine
por: Cao, Yunlong, et al.
Publicado: (2021)

A Roadmap for Future Parkinson's Pharmacogenomics in Asia
por: Akbar, Muhammad, et al.
Publicado: (2022)

ANCA-associated vasculitis following the CoronaVac vaccination
por: Ma, Yaohui, et al.
Publicado: (2022)

Boosting immunity after CoronaVac
por: Sester, Martina, et al.
Publicado: (2022)

Reduced CoronaVac vaccine antibody response in patients with chronic kidney disease
por: Akpolat, Tekin
Publicado: (2021)

CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Longitudinal evaluation of innate immune responses to three doses of CoronaVac vaccine
por: Cao, Cheng, et al.
Publicado: (2023)

Association between GPER gene polymorphisms and GPER expression levels with cancer predisposition and progression
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2021)

The prevalence of anxiety symptoms and disorders among ophthalmic disease patients
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2022)

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
por: Li, Jingxin, et al.
Publicado: (2022)

Antibody dynamics post-Comirnaty and CoronaVac vaccination in Malaysia
por: Tan, Cheng Siang, et al.
Publicado: (2022)

A Rare Adverse Event after CoronaVac(®)Administration: Neutropenia in a Kidney Transplant Recipient
por: Artan, Ayşe Serra, et al.
Publicado: (2022)

CoronaVac efficacy data from Turkey
por: McMenamin, Martina E, et al.
Publicado: (2021)

Evaluation and follow-up of antibody formation after CoronaVac vaccine
por: Çalişir, Büşra, et al.
Publicado: (2022)

Phenotypic and functional changes of T cell subsets after CoronaVac vaccination
por: Phoksawat, Wisitsak, et al.
Publicado: (2022)

BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses among Transplant Recipients Who Had Received Two Doses of CoronaVac
por: Erol, Çiğdem, et al.
Publicado: (2023)

CoronaVac: more data for regulators and policy makers
por: Ramasamy, Maheshi N, et al.
Publicado: (2021)

Humoral Immune Response to CoronaVac in Turkish Adults
por: Cosgun, Yasemin, et al.
Publicado: (2023)

Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey
por: Sonmezer, Meliha Cagla, et al.
Publicado: (2022)

Factors Associated with Vaccine Breakthrough Incidence among Health Care Workers Vaccinated with Inactivated SARS-CoV-2 Vaccine (CoronaVac)
por: Anshory, Muhammad, et al.
Publicado: (2022)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
por: Goh, Yun Shan, et al.
Publicado: (2022)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
Publicado: (2023)

Neutralizing antibodies induced by homologous and heterologous boosters in CoronaVac vaccines in Chile
por: Acevedo, Johanna, et al.
Publicado: (2023)

SARS-CoV-2 Breakthrough Infection after mRNA-1273 Booster among CoronaVac-Vaccinated Healthcare Workers
por: Santi, Theresia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h101nlk733lum92p6p4hirv0vv